BrainScope announced that it launched its third FDA-cleared algorithm for concussion diagnosis on the BrainScope device.
Bethesda, Md.–based BrainScope’s Concussion Index is the first physiological marker of concussive injury that aids clinicians in the assessment of patients at baseline, point of injury and through recovery, according to a news release.
The index adds to BrainScope’s already available suite of FDA-cleared algorithms for clinical use in rapidly triaging suspected mild traumatic brain injuries, from brain bleeds to concussions. The company touts the platform as capable of reducing the use of head CAT scans by more than 30% when used by emergency departments.
Connected through a disposable headset, a handheld device acquires, processes and analyzes thousands of brain activity-based physiological parameters, morphing them into a single index by using AI algorithms. Results are made immediately available to allow doctors to obtain rapid insights.
BrainScope’s device and headsets are available through the company and must be used with a physician’s order.
“With the addition of the AI-derived Concussion Index, BrainScope adds important new baselining and follow-up capabilities to aid physicians in concussion management,” BrainScope CEO Susan Hertzberg said in the release. “The device operates on a battery charge, making it an ideal choice for assessments on the playing fields or battlefields. BrainScope does not require a blood draw or processing in a lab – it is completely non-invasive, truly point-of-care and takes less than 20 minutes from patient prep to results.”